中文 | English
Return
Total: 217 , 1/22
Show Home Prev Next End page: GO
Author:( Xinxin YANG)

2.Determination of Plasma Concentration of Caffeine,Dapsone and Chlorzoxazone by Solid Phase Extrac-tion-HPLC and Pharmacokinetic Study

Haibo WANG ; Xinxin YANG ; Xue DI

China Pharmacy 2015;(34):4770-4772

3.Clinical Study on Fluticasone Furoate Nasal Spray in the Treatment of Allergic Rhinitis

Chen YANG ; Xinxin WEI ; Zhongpu YIN

China Pharmacy 2017;28(11):1503-1506

4.Surgical treatment of lung cancer in the elderly

Yuanyuan TAN ; Xinxin ZOU ; Yang XIE ; Lei ZHANG

Journal of International Oncology 2012;39(4):289-291

5.β-arrestin1 mediates the effect of MK-801 on levodopa-induced dyskinesia in Parkinson ', s disease

Na WU ; Lu SONG ; Xinxin YANG ; Zhenguo LIU

Chinese Journal of Neurology 2011;44(9):597-601

6.Viral dynamics during entecavtr therapy in patients with chronic hepatitis B

Bilian YAO ; Xinxin ZHANG ; Jing YANG ; Demin YU ; Donghua ZHANG

Chinese Journal of Infectious Diseases 2009;27(6):338-342

7.Clinical Application of Extraction and Analysis of the Key Frames Based on IVUS Sequences.

Haiqun MAO ; Feng YANG ; Zheng HUANG ; Kai CUI ; Xinxin WANG

Journal of Biomedical Engineering 2015;32(4):892-899

8.Study on Molecular Composition of Bismuth Potassium Citrate

Xiumei LI ; Yuan YUAN ; Liu YANG ; Xinxin ZHAO

China Pharmacist 2014;(11):1821-1825

9.Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease.

Na WU ; Lu SONG ; Xinxin YANG ; Jianglei WEI ; Zhenguo LIU

Journal of Integrative Medicine 2012;10(9):1018-24

10.Relationship between G protein-coupled receptor kinase 6 and N-methyl-D-aspartate receptor in the mechanism study underlying motor complications in Parkinson's disease

Na WU ; Xinxin YANG ; Lu SONG ; Zhenguo LIU

Chinese Journal of Geriatrics 2011;30(4):327-331

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 217 , 1/22 Show Home Prev Next End page: GO